Pharmaceutical Disruption: Are Compounding Pharmacies a Friend or Foe?

23rd January 2025
1. Introduction In the dynamic landscape of drug development and distribution, compounding pharmacies have come to play an important role in addressing unique patient needs. However, their presence...
Learn More

Cancer Immunotherapy: Can Antifibrotics Unlock the Door to Cold Tumors?

03rd January 2025
Introduction Cancer immunotherapy has revolutionized the landscape of cancer treatment, shifting the paradigm from non-specific, cytotoxic approaches to strategies that harness the body’s immune...
Learn More

Senotherapy: The battle for quality vs quantity of life

12th September 2024
Introduction By the year 2050, more than 2 billion individuals will be over age 60.1 At the same time, advances in healthcare and standards of living have resulted in an increase in lifespan for...
Learn More

AI in Small-Molecule Drug Discovery: Black Box or Crystal Ball?

07th December 2023
1. Intro: Artificial intelligence (AI) and machine learning (ML) have become household buzzwords across virtually every domain of science and technology. Beyond the academic sphere, the advent of...
Learn More

Pharma Licensing Interests: The Updated Wish List of 56 Big Pharma Companies

16th August 2023
Intro: Over the past two decades, there has been a major shift in the Big Pharma R&D model. In the face of declining efficiencies and increases in both cost and timing for the successful approval and...
Learn More

The iPSC Clinical Landscape: A Bright Future Ahead

28th June 2023
I. Intro Cell and gene therapies (CGT) are transforming how biopharma companies treat and potentially cure certain diseases. From viral vectors to CAR-T cells, the landscape of CGTs is evolving...
Learn More

Next Generation Chemotherapy: Life in the Old Dog Yet

29th May 2023
Introduction: In biotech and pharma, it’s fair to say that cancer chemotherapy has fallen out of fashion, with interest shifting predominantly to targeted therapies and immunotherapy. Investors seem...
Learn More

Unlocking iPSCs to Improve CNS Modeling and Drug Discovery

09th June 2022
Introduction: To date, therapeutic advances in treating central nervous system (CNS) disorders have been incremental at best. As the global population increases and older demographics begin to make...
Learn More

Exosome & Extracellular Vesical-Based Therapeutics & Their Potential Use in Oncology

12th November 2021
Abstract It was previously believed that exosomes, membrane-bound extracellular vesicles released by cells, were a waste disposal mechanism resulting from cell damage or from by-products of cell...
Learn More

The emerging landscape of RNA-targeted small molecules

17th September 2021
Intro: For decades, conventional drug strategy has relied on the ability of small molecules to either inhibit or alter protein function by targeting their active sites. While this was instrumental in...
Learn More

Replacing the Surrogates: Beyond In Vivo Preclinical Models

24th August 2021
Intro: Animal modelling is a staple of preclinical drug development and in most countries a legal requirement before entering human trials. However, these experiments are time-consuming, expensive,...
Learn More

What's on Pharma's Licensing Wish List?

04th August 2021
Asset licensing, mergers, and acquisitions have become an integral pipeline expansion strategy for Pharma. The realization over the past two decades that productivity of internal R&D alone is...
Learn More
1 2 3 4
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-25 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.